Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 14/20 | 0.37 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23353650 | 0.94 | GHSR (0.36) | GHSRTAS2R14NPC1POLBPARP1 | |
| SCHEMBL23327005 | 0.91 | TAS2R14 (0.35) | TAS2R14NPC1POLBPARP1 | |
| SCHEMBL21470704 | 0.90 | GHSR (0.37) | GHSRTAS2R14PARP1NR1H2NR1H3 | |
| SCHEMBL21470487 | 0.89 | GHSR (0.36) | GHSRTAS2R14HTR6PARP1NR1H2 | |
| SCHEMBL23353525 | 0.89 | GHSR (0.38) | GHSRTAS2R14HTR6PARP1 | |
| SCHEMBL21470700 | 0.86 | GHSR (0.36) | GHSRTAS2R14HTR6PARP1 | |
| SCHEMBL21470766 | 0.85 | HTR6 (0.39) | GHSRTAS2R14HTR6 | |
| SCHEMBL21470772 | 0.84 | GHSR (0.35) | GHSRNPC1POLBPARP1 | |
| SCHEMBL23326955 | 0.83 | TAS2R14 (0.35) | TAS2R14NPC1POLBPARP1 | |
| SCHEMBL23326956 | 0.83 | TAS2R14 (0.35) | TAS2R14NPC1POLBPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139484-A1 | DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | GOSSAMER BIO SERVICES INC (US) | 2021-05-13 | — | — | US | disclosed |
| WO-2019200120-A1 | DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | LYCERA CORPORATION (US) | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139484-A1 | DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | ULK1, PHKG2, PHKG1 | GHSR 2448/4885TAS2R14 4112/4885NPC1 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.